<DOC>
	<DOCNO>NCT00002734</DOCNO>
	<brief_summary>Phase I trial study effectiveness radiolabeled monoclonal antibody , paclitaxel , interferon alfa treat patient ovarian cancer . Radiolabeled monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Interferon may interfere growth cancer cell . Combining monoclonal antibody , chemotherapy , interferon alfa may kill tumor cell .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody , Paclitaxel , Interferon Alfa Treating Patients With Recurrent Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) intraperitoneal paclitaxel topotecan administer radiosensitizer prior intraperitoneal lutetium Lu 177 monoclonal antibody CC49 ( 177Lu-CC49 ) follow subcutaneous interferon alfa-2b ( IFN-A ) patient persistent recurrent ovarian cancer . II . Determine toxicity associate intraperitoneal paclitaxel topotecan patient . III . Examine conjugate stability , pharmacokinetics , biodistribution 177Lu-CC49 give 48 hour intraperitoneal paclitaxel . IV . Determine effect IFN-A intraperitoneal paclitaxel 177Lu-CC49 tumor localization dosimetry estimate compare prior trial 177Lu-CC49 alone . V. Determine MTD yttrium Y 90 monoclonal antibody CC49 ( 90Y-CC49 ) administer IFN-A dose paclitaxel use MTD level IFN-A , paclitaxel , 177Lu-CC49 . VI . Monitor antitumor effect treatment patient . OUTLINE : This dose escalation study paclitaxel , topotecan , lutetium LU 177 monoclonal antibody CC-49 ( 177Lu-CC49 ) , yttrium Y 90 monoclonal antibody CC49 ( 90Y-CC49 ) . Patients receive interferon alfa subcutaneously day 1 , 3 , 5 , 7 ; paclitaxel intraperitoneally ( IP ) day 4 topotecan IP day 6 ; 177Lu-CC49 IP day 6 . Treatment continue every 6 week 2 course absence disease progression unacceptable toxicity . Cohorts 3-5 patient receive escalate dos paclitaxel decrease dos 177Lu-CC49 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 3 5 patient experience dose limit toxicity . Once MTD paclitaxel determine , dose 177Lu-CC49 escalate . Once MTD 177Lu-CC49 determine , 90Y-CC49 substitute . The MTD 90Y-CC49 determine administer paclitaxel . Topotecan substitute paclitaxel ( administer MTD 177Lu-CC49 interferon alfa ) escalate MTD determine . Patients follow 6 week every 3 month 1 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma ovary papillary serous carcinoma extraovarian origin Recurrent persistent follow standard surgery 1 2 chemotherapy regimen ( without paclitaxel ) , i.e . : persistent disease progression chemotherapy nodule less equivalent 5 x 5 x 5 cm Recurrent carcinoma ( primary secondary chemotherapy ) detect clinically either exam rise CA 125 radiographic evidence disease great equivalent 5 x 5 x 5 cm nodule Residual disease le 5 x 5 x 5 cm follow reassessment laparotomy Microscopic residual disease reassessment laparotomy chemotherapy Tumor TAG72 positive immunoperoxidase stain original current tumor block At least 85 % free flow fluid peritoneal cavity demonstrate technetium99m scan imaging within 2 week prior treatment No evidence disease outside peritoneal cavity retroperitoneal lymphadenopathy No massive ascites PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 WBC least 3,500/mm3 Platelet count least 125,000/mm3 Hemoglobin great 9 g/dL No nucleate RBC significant teardrop RBC morphology Bilirubin le 1.5 mg/dL AST/ALT le 4 time normal Creatinine le 2.0 mg/dL HIV negative Hepatitis B surface antigen negative No hypersensitivity paclitaxel , polyoxethylated castor oil , topotecan No malignancy past 5 year except basal cell skin carcinoma Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : At least 3 week since prior biologic therapy recover No prior monoclonal antibody therapy No concurrent immunotherapy No prior bone marrow stem cell transplantation At least 3 week since prior chemotherapy ( 6 week since nitrosoureas mitomycin ) recover No concurrent chemotherapy At least 3 week since prior radiotherapy recover No prior radiotherapy abdominal cavity No concurrent radiotherapy At least 3 week since prior major surgery recover No prior intraperitoneal therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2001</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>